These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38417455)

  • 61. Reliably picking the best endpoint.
    Follmann D
    Stat Med; 2018 Dec; 37(29):4374-4385. PubMed ID: 30091264
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A systematic comparison of recurrent event models for application to composite endpoints.
    Ozga AK; Kieser M; Rauch G
    BMC Med Res Methodol; 2018 Jan; 18(1):2. PubMed ID: 29301487
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Comparative Methodological Assessment of the Randomized GLOBAL LEADERS Trial Using Total Ischemic and Bleeding Events.
    Hara H; van Klaveren D; Takahashi K; Kogame N; Chichareon P; Modolo R; Tomaniak M; Ono M; Kawashima H; Wang R; Gao C; Niethammer M; Fontos G; Angioi M; Ribeiro VG; Barbato E; Leandro S; Hamm C; Valgimigli M; Windecker S; Jüni P; Steg PG; Verbeeck J; Tijssen JGP; Sharif F; Onuma Y; Serruys PW;
    Circ Cardiovasc Qual Outcomes; 2020 Aug; 13(8):e006660. PubMed ID: 32762446
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Statistical power considerations in the use of win ratio in cardiovascular outcome trials.
    Wang B; Zhou D; Zhang J; Kim Y; Chen LW; Dunnmon P; Bai S; Liu Q; Ishida E
    Contemp Clin Trials; 2023 Jan; 124():107040. PubMed ID: 36470557
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Evaluation of Adjusted and Unadjusted Indirect Comparison Methods in Benefit Assessment. A Simulation Study for Time-to-event Endpoints.
    Kühnast S; Schiffner-Rohe J; Rahnenführer J; Leverkus F
    Methods Inf Med; 2017 May; 56(3):261-267. PubMed ID: 28361159
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency.
    Anker SD; Schroeder S; Atar D; Bax JJ; Ceconi C; Cowie MR; Crisp A; Dominjon F; Ford I; Ghofrani HA; Gropper S; Hindricks G; Hlatky MA; Holcomb R; Honarpour N; Jukema JW; Kim AM; Kunz M; Lefkowitz M; Le Floch C; Landmesser U; McDonagh TA; McMurray JJ; Merkely B; Packer M; Prasad K; Revkin J; Rosano GM; Somaratne R; Stough WG; Voors AA; Ruschitzka F
    Eur J Heart Fail; 2016 May; 18(5):482-9. PubMed ID: 27071916
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Testing for qualitative heterogeneity: An application to composite endpoints in survival analysis.
    Oulhaj A; El Ghouch A; Holman RR
    Stat Methods Med Res; 2019 Jan; 28(1):151-169. PubMed ID: 28670972
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Addressing multiplicity issues of a composite endpoint and its components in clinical trials.
    Huque MF; Alosh M; Bhore R
    J Biopharm Stat; 2011 Jul; 21(4):610-34. PubMed ID: 21516560
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Adjusted win ratio using the inverse probability of treatment weighting.
    Wang D; Zheng S; Cui Y; He N; Chen T; Huang B
    J Biopharm Stat; 2023 Nov; ():1-16. PubMed ID: 37947400
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Composite End Points in Acute Heart Failure Research: Data Simulations Illustrate the Limitations.
    Brown PM; Anstrom KJ; Felker GM; Ezekowitz JA
    Can J Cardiol; 2016 Nov; 32(11):1356.e21-1356.e28. PubMed ID: 27499377
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Consistency-ensured parametric tests for critical events of composite endpoints.
    Huque MF; Alosh M; Guerra M
    J Biopharm Stat; 2018; 28(1):82-98. PubMed ID: 29144871
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Management of Renin-Angiotensin-Aldosterone System blockade in patients admitted to hospital with confirmed coronavirus disease (COVID-19) infection (The McGill RAAS-COVID- 19): A structured summary of a study protocol for a randomized controlled trial.
    Aflaki M; Flannery A; Ferreira JP; Cheng MP; Kronfli N; Marelli A; Zannad F; Brophy J; Afillalo J; Huynh T; Giannetti N; Bessissow A; Ezekowitz JA; Lopes RD; Ambrosy AP; Craig M; Sharma A
    Trials; 2021 Feb; 22(1):115. PubMed ID: 33546734
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Prioritised endpoints for device-based hypertension trials: the win ratio methodology.
    Kandzari DE; Hickey GL; Pocock SJ; Weber MA; Böhm M; Cohen SA; Fahy M; Lamberti G; Mahfoud F
    EuroIntervention; 2021 Apr; 16(18):e1496-e1502. PubMed ID: 33226002
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Composite endpoints.
    Palileo-Villanueva LM; Dans AL
    J Clin Epidemiol; 2020 Dec; 128():157-158. PubMed ID: 32739473
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized Clinical Trials.
    Claggett B; Pocock S; Wei LJ; Pfeffer MA; McMurray JJV; Solomon SD
    Circulation; 2018 Aug; 138(6):570-577. PubMed ID: 29588314
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Use of composite endpoints in clinical trials.
    Sankoh AJ; Li H; D'Agostino RB
    Stat Med; 2014 Nov; 33(27):4709-14. PubMed ID: 24833282
    [TBL] [Abstract][Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.